Germany’s Lucid Genomics secures €1.3M to advance AI-driven genetic insights for faster drug discovery

Berlin-based Lucid Genomics, a healthtech startup, has secured €1.3M in a pre-seed round of funding led by Caesar Ventures, with additional contributions from BIF Partners, Another.vc, and the MPF Accelerator Program.

Lucid Genomics’ platform provides AI-powered solutions that turn all genetic data into insights for faster drug discovery. This funding will accelerate the expansion of Lucid Genomics’ AI-Digital HealthTech platform.

Translating genetic information into valuable insights

According to Lucid Genomics, whole genome sequencing promises to transform precision medicine, gene editing, and pharmacogenomics, yet current methods often miss the “dark genome” – non-coding regions making up 98 per cent of our DNA.

Building on this foundation, Lucid Genomics has developed advanced machine-learning algorithms that enhance genetic variant detection by focusing on both coding and non-coding regions.

Its comprehensive framework interprets all genetic mutations, offering a more holistic understanding of genetic variations and their impact on human health.

Lucid Genomics will expand its digital healthtech platform by analysing 100 per cent of DNA data to refine genetic mutation identification and provide more accurate insights. 

The initial focus will be on rare genetic diseases, with plans to later expand into cancer diagnostics and related areas.

Lucid Genomics mentions in a statement, “Our unique strength lies in our expertise across three key areas: cutting-edge DNA sequencing technologies, advanced AI in genomics, and a deep understanding of the ‘dark genome’. This powerful combination has been instrumental in founding Lucid Genomics.”

“We anticipate a ‘Genomic Revolution’ transforming healthcare, and we’re committed to positioning Lucid Genomics as a pioneer in this exciting field.”

“Our vision is for our SaaS platform to evolve into a comprehensive digital solution capable of processing 100 per cent of any DNA sequencing data. This will have a profound impact on cancer screening, drug discovery, and clinical trials.”

Brief about Lucid Genomics

Lucid Genomics was founded by Uirá Souto Melo and Hossein Moeinzadeh, building on the research of Prof. Dr. Stefan Mundlos and Prof. Dr. Martin Vingron from the Max Planck Institute for Molecular Genetics and Charité – Universitätsmedizin Berlin.

The platform’s development was backed by accelerator programmes, including MAX!mize (which provided €270K in non-dilutive investment), and the mentorship, co-working space, and community provided by Start2 Group and K.I.E.Z AI.